New hope for transplant patients battling dangerous immune reaction

This study is testing whether adding an experimental drug called Gecacitinib to standard steroid treatment can better control acute Graft-Versus-Host Disease (aGVHD) in adults who recently received a stem cell transplant. The trial will enroll 25 patients with moderate to severe aGVHD to see how well they respond after 28 days of combined treatment. Researchers want to determine if this new approach helps more patients achieve significant improvement compared to current standard care.